Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients

Table 1 Demographic and baseline clinical characteristics of FD patients with nocturnal dyspeptic symptoms n (%)

Characteristic	Placebo	Domperidone
Age (yr)
mean ± SD	44.5 ± 8.6	43.9 ± 9.8
Range	25-56	22-50
Gender
Male	6 (40)	7 (46.7)
Female	9 (60)	8 (53.3)
BMI (kg/m2)
mean ± SD	21.3 ± 7.9	20.7 ± 8.1
Range	18.4-27.2	18.0-25.1
Current smokers	1 (4.2)	3 (5.9)
Alcohol use	5 (22.7)	6 (11.8)
Positive for Helicobacter pylori	0 (0)	0 (0)

FD: Functional dyspepsia; BMI: Body mass index.

Table 2 Effect of domperidone on nocturnal duodenogastric bile reflux and gastric pH in FD patients with nocturnal dyspeptic symptoms (mean ± SD)

Group	n	% of bile reflux time		Gastric pH
		Baseline	After treatment	Baseline	After treatment
Placebo	15	3.4 ± 1.3	3.4 ± 1.5	4.9 ± 1.2	4.7 ± 1.1
Domperidone	15	3.5 ± 1.7	1.1 ± 0.6a	5.2 ± 1.5	2.8 ± 0.9a

^aP < 0.05 vs baseline.

Table 3 Pearson R-values for improved nocturnal dyspeptic symptoms and reduced nocturnal bile reflux or gastric pH in domperidone-treated FD patients

	% of bile reflux time	Gastric pH
Epigastric pain/discomfort	0.736a	0.679a
Abdominal distention	0.784a	0.715a
Belching	0.753a	0.697a

^aP < 0.05.